On May 27, the U.S. Food and Drug Administration (FDA) approved Viberzi (eluxadoline) and Xifaxan (rifaximin) for irritable bowel syndrome with diarrhea in adult men and women. Read…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.